Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

U.S. net sales of EYLEA were $736 million, down 39% year-over-year, impacted by increased use of off-label Avastin and lower wholesaler inventory levels. EYLEA HD sales reached $307 million ...

Avastin, while mainly used to treat cancer, works similarly to Eylea by blocking the vascular endothelial growth factor (VEGF) protein, which plays a key role in the formation of blood vessels.

Eylea HD certainly also is one of the very strong ... So we are limiting these users for pretty much moving these patients who are on Avastin to switch them to either to Pavblu or Byooviz.

Eylea, or aflibercept, had global sales of just under $10 billion in 2024, thanks to its strong competitive positioning and more attractive dosing regimen versus Lucentis and Avastin in ...

Regulatory delays impacting EYLEA HD’s pre-filled syringe approval could hinder adoption. Increased market share of off-label Avastin poses a challenge to the anti-VEGF category. Analysts raised ...